| Popis: |
Precision medicine, which considers the genetics of the tumor tissues and cells for selection of the most appropriate treatment strategy, has recently been developed for colorectal cancer. The BRAF mutation status in colorectal cancer has been tested, but precision medicine for BRAF-mutated tumors had not been applicable due to no approved BRAF-targeting drugs until recently. In addition, conventional standard chemotherapy for BRAF-mutated colorectal cancer show limited effectiveness, resulting in poor prognosis. Therefore, we need new drugs specific for BRAF-mutated colorectal cancer. In this review, we outline the characteristics, development, and new treatment strategies for BRAF-mutated colorectal cancer. In addition, we introduce the BEACON CRC study, which prospectively evaluated the efficacy and safety of combination therapy of encorafenib(BRAF inhibitor), binimetinib(MEK inhibitor), and cetuximab(anti-EGFR antibody)in patients with metastatic colorectal cancer with the BRAF V600E-mutation. |
